Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. / Ross, C; Clemmesen, K M; Sørensen, P S; Koch-Henriksen, Nils; Bendtzen, K.

I: Multiple Sclerosis, Bind 12, Nr. 1, 01.02.2006, s. 39-46.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ross, C, Clemmesen, KM, Sørensen, PS, Koch-Henriksen, N & Bendtzen, K 2006, 'Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis', Multiple Sclerosis, bind 12, nr. 1, s. 39-46.

APA

Ross, C., Clemmesen, K. M., Sørensen, P. S., Koch-Henriksen, N., & Bendtzen, K. (2006). Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Multiple Sclerosis, 12(1), 39-46.

Vancouver

Ross C, Clemmesen KM, Sørensen PS, Koch-Henriksen N, Bendtzen K. Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. Multiple Sclerosis. 2006 feb. 1;12(1):39-46.

Author

Ross, C ; Clemmesen, K M ; Sørensen, P S ; Koch-Henriksen, Nils ; Bendtzen, K. / Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. I: Multiple Sclerosis. 2006 ; Bind 12, Nr. 1. s. 39-46.

Bibtex

@article{b282303d7fd14ebfa320ec8322d8ed97,
title = "Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis",
abstract = "Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P",
author = "C Ross and Clemmesen, {K M} and S{\o}rensen, {P S} and Nils Koch-Henriksen and K Bendtzen",
year = "2006",
month = feb,
day = "1",
language = "English",
volume = "12",
pages = "39--46",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications",
number = "1",

}

RIS

TY - JOUR

T1 - Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis

AU - Ross, C

AU - Clemmesen, K M

AU - Sørensen, P S

AU - Koch-Henriksen, Nils

AU - Bendtzen, K

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P

AB - Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P

M3 - Journal article

VL - 12

SP - 39

EP - 46

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

SN - 1352-4585

IS - 1

ER -

ID: 34092834